Lantheus Holdings (LNTH) Other Non-Current Assets (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Other Non-Current Assets of $61.7 million for Q1 2026, up 69.31% year-over-year from $36.5 million in Q1 2025, and down 23.53% quarter-over-quarter from $80.7 million in Q4 2025.
Lantheus Holdings (LNTH) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Other Non-Current Assets for 13 consecutive years, with $61.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 69.31% year-over-year to $61.7 million; the TTM figure through Mar 2026 stood at $61.7 million (up 69.31% YoY), while the FY2025 annual figure was $80.7 million, up 82.52% from the prior year.
- Other Non-Current Assets retreated to $61.7 million in Q1 2026 per LNTH's latest filing, from $80.7 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $80.7 million in Q4 2025 and bottomed at $7.2 million in Q3 2023.
- Historically, Other Non-Current Assets has averaged $32.7 million across 5 years, with a median of $36.5 million in 2025.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets slumped 82.94% — and 2025, when it jumped 650.4%.
- Lantheus Holdings' Other Non-Current Assets stood at $34.4 million in 2022, then tumbled by 79.16% to $7.2 million in 2023, then surged by 517.92% to $44.2 million in 2024, then soared by 82.52% to $80.7 million in 2025, then retreated by 23.53% to $61.7 million in 2026.
- Business Quant data shows LNTH's Other Non-Current Assets at $61.7 million in Q1 2026, $80.7 million in Q4 2025, and $53.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 13.00 Mn |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | 59.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.72 Mn |
| Mar 31, 2026 | 61.74 Mn |
| Dec 31, 2025 | 80.74 Mn |
| Sep 30, 2025 | 53.72 Mn |
| Jun 30, 2025 | 36.39 Mn |
| Mar 31, 2025 | 36.47 Mn |
| Dec 31, 2024 | 44.24 Mn |
| Sep 30, 2024 | 7.16 Mn |
| Jun 30, 2024 | 7.16 Mn |
| Mar 31, 2024 | 7.16 Mn |
| Dec 31, 2023 | 7.16 Mn |
| Sep 30, 2023 | 7.16 Mn |
| Jun 30, 2023 | 39.13 Mn |
| Mar 31, 2023 | 7.20 Mn |
| Dec 31, 2022 | 34.36 Mn |
| Sep 30, 2022 | 41.63 Mn |
| Jun 30, 2022 | 42.16 Mn |
| Mar 31, 2022 | 42.20 Mn |
| Dec 31, 2021 | 38.76 Mn |
| Sep 30, 2021 | 45.29 Mn |